CompletedPhase 3NCT00262795

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Studying B-cell chronic lymphocytic leukemia

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: German CLL Study Group
Principal Investigator: Michael Hallek, MD
Medizinische Universitaetsklinik I at the University of Cologne
Intervention: Fludarabine(drug)
Enrollment: 206 enrolled
Eligibility: 65-79 years · All sexes
Timeline: 2003 – 2005

Study locations (30)

Hanuschkrankenhaus, Vienna, Austria
Klinikum St. Marien, Amberg, Germany
Gemeinschaftspraxis Fuer Innere Medizin, Haematologie Und Internistische Onkologie, Ansbach, Germany
Zentralklinikum Augsburg, Augsburg, Germany
Humaine - Clinic, Bad Saarow, Germany
Krankenhaus Hohe Warte Mediziniche Klinik, Bayreuth, Germany
Onkologisches Versorgungszentrum Friedrichshain, Berlin, Germany
Internistische Gemeinschaftspraxis - Berlin, Berlin, Germany
Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany
Charite - Campus Virchow Klinikum, Berlin, Germany
Saint Josef - Hospital Bochum, Bochum, Germany
Praxis Dres. F.& G. Doering, Bremen, Germany
Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany
Onkologische Schwerpunktpraxis, Cottbus, Germany
Onkologische Gemeinschaftspraxis - Dresden, Dresden, Germany
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00262795 on ClinicalTrials.gov

Other trials for B-cell chronic lymphocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for B-cell chronic lymphocytic leukemia →

← Back to all trials